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Abstract:  
Introduction: Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency 
is a debilitating and potentially lethal disease. Management includes on-demand 
treatment of angioedema and their prophylaxis. Plasma derived C1-INH is an 
established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a 
recombinant form of human C1-INH (rhC1-INH) produced in transgenic rabbits. It 
has granted drug’s registration as treatment option for acute HAE attacks in adults 
and adolescents in Europe, America, and other countries. Long-term prophylaxis 
with rhC1-INH received recent consideration in clinical trials.  
Areas covered: This review will critically appraise available information about rhC1-
INH (conestat alfa) prophylactic treatment in adult and adolescent patients with 
congenital C1-INH deficiency. Results from a phase II randomized placebo-
controlled trial for prophylaxis of severe HAE evidenced positive treatment outcomes 
for its application, both twice or once weekly.  
Expert commentary: Phase II clinical studies suggest that rhC1-INH is a viable 
option for prophylaxis of HAE. Safety and tolerability data are comparable to other 
available HAE specific drugs, zeroing the possibility for blood-born viral transmission. 
Sustainability of modern technologies is granting a practically stable and continuous 
recombinant production process. With other available options, rhC1-INH facilitates 
tailoring HAE treatment to patients’ needs. 
 
  
Page 2 of 36
URL: https://mc.manuscriptcentral.com/erm   Email: jonathan.patience@informa.com
Expert Review of Clinical Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 3
1. Introduction and overview of the market 
Hereditary angioedema due to C1 inhibitor deficiency, hereafter HAE, is an 
autosomal dominant genetic disease characterized by recurrent attacks of 
subcutaneous and submucosal swellings. The pathophysiological mechanism 
involves activation of the contact system and release of the vasoactive peptide 
bradykinin that increases vascular permeability [1-3] (Figure 1). The underlying 
genetic defect is in SERPING1 gene that codes for C1-INH protein. Mutations in one 
of the two alleles result in low plasma concentration of C1-INH (HAE Type 1), or in 
low functional plasma levels, due secretion of an antigenically identical dysfunctional 
protein product (HAE Type 2). Both types have identical impact on the enzymatic 
systems controlled by C1-INH and cause identical clinical phenotypes [4]. Mutations 
reported to be pathogenic for HAE are affecting the C-terminal of the C1 inhibitor 
molecule [5], and only one missense mutation in the N-terminal can be related to 
clinical symptoms of angioedema [6]. 
HAE manifestations can affect different locations: facial and peripheral subcutaneous 
angioedema attacks which are disabling, disfiguring and painful; and abdominal 
mucosal swellings which cause severe pain, and could mimic an emergency surgical 
condition, ‘acute abdomen’, possibly resulting in unnecessary invasive iatrogenic 
procedures [7][8,9]. The most serious disease manifestations are the laryngeal 
attacks, which can lead to death by asphyxiation and are the primary cause for the 
high mortality rate associated with the disease [10].  
Current HAE treatment strategies include 1) on demand therapy (ODT) to revert 
acute manifestations, 2) long-term prophylaxis (LTP) to avoid/reduce angioedema 
recurrences and 3) short-term prophylaxis (STP) for attack prevention in high risk 
Page 3 of 36
URL: https://mc.manuscriptcentral.com/erm   Email: jonathan.patience@informa.com
Expert Review of Clinical Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 4
circumstances [11]. Upon diagnosis and lifelong thereafter, all HAE patients should 
be enabled to immediate use of ODT at appearance of angioedema, to avoid 
disease mortality and to shorten attack duration. When this approach does not lead 
to satisfactory disease control, LTP should be considered to restore normal activities 
and improve patients’ quality of life (QoL) [11]. 
Several drugs have specific approval for HAE treatment, although with country 
differences in indication and availability. Plasma derived C1-INHs have indications 
for both ODT and LTP [12,13]. The bradykinin receptor antagonist icatibant, the 
kallikrein inhibitor kalbitor and the recombinant C1-INH conestat alfa are approved 
just for ODT [14,15]. On the opposite, attenuated androgens are exclusively 
approved for LTP [16]. In several countries, fresh frozen plasma is the only resource 
for ODT. Where multiple options are available, choosing among treatments for ODT 
mainly rely on patient’s preferences based on administration route (intravenous or 
subcutaneous) and perceived efficacy. In LTP, benefits expected from a therapy 
should receive careful evaluation against side effects: this is particularly difficult 
when long-term side effects need to be envisaged from drug characteristics in 
absence of epidemiological evidence.  
For decades, cost/benefit balance has been the dilemma of attenuated androgens. 
Their high clinical efficacy in preventing HAE symptoms, needs to be weight against 
a long list of potential side effects in absence of studies confirming any treatment-
related increased morbidity [17]. Ten years ago intravenous pdC1-INH was approved 
for LTP. A subcutaneous formulation of pdC1-INH was approved for LPT in U.S. in 
2017 and will soon reach Europe [18]. The same route of administration is used by 
lanadelumab, a monoclonal antibody blocking kallikrein for several weeks. This 
compound successfully completed phase III and is now filing for approval in LTP 
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[19]. Again targeted to kallikrein is an oral small molecule that is now entering phase 
III trial [20]. It is likely that safety shown in other genetic disorders will render gene 
therapy an appealing approach to completely revert HAE [21].  
Considering the large array of effective treatments, we can see LTP approach to 
HAE aimed at identifying the most physiological and safe drug. Reverting HAE 
patients to normal clinical and biochemical phenotype is the objective of C1-INH 
replacing approaches. It has been first attempted using the plasma-derived protein. 
Therapies based on plasma-derived proteins started in the seventies when main 
problem were purity and blood borne infections [22]. These problems were 
minimized over the years and pdC1-INH preparations are highly purified with an 
excellent safety profile. Both viral safety and purity are guaranteed by accurate 
monitoring and a purification process abating different infectious agents and leading 
to final product close to 100% purity [23-25]. The clinical experience with the pdC1-
INH available at present shows no report of infection and high clinical efficacy for 
both ODT and LTP suggesting that the purification process does not affect protein 
pharmacodynamics [26]. In the second half of 2017 a shortage in availability of 
pdC1-INH was faced worldwide, due to difficulties to rapidly scale production based 
on request. This is a well-known problem of plasma based products. As a solution to 
this, and other above mentioned problems with plasma derived products, 
recombinant proteins as human therapy became an interesting alternative [27]. The 
same applies to C1-INH, with the recombinant product (rhC1-INH) conestat alfa, 
currently available as a marketed pharmaceutical product for treatment on HAE. It is 
produced in the mammary gland cells and secreted into the milk of transgenic rabbits 
and then purified for use in humans [28]. 
Efficacy and safety of rhC1-INH for ODT in HAE patients, have been investigated  in 
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several randomized placebo-controlled trials, as well as in open-label studies [15,29-
32]. Conestat alfa (Ruconest®) is currently approved for acute HAE treatment in 
Europe, the US, Israel and South Korea. The product is available on a named-
patient basis in other territories where it has not yet obtained marketing 
authorization. Recently, rhC1-INH has shown to be efficacious and well tolerated as 
a prophylaxis option in a randomized, placebo-controlled crossover trial [33]. The 
results of this study supported the initial proof of concept open-label prophylaxis 
study [34], and sporadic case reports of efficacy in LTP and STP [35]. 
In this publication we will critically review the up-to-date available literature, and also 
try to address the missing points in current knowledge to explain how rhC1-INH is 
efficacious as a treatment for prophylaxis of HAE. 
2. Body of review 
2.1. Why recombinant human C1-INH from transgenic rabbits? 
We already pointed to the relevance for safe and effective treatment to reverse 
effects of HAE on patients’ life. Knowledge, awareness and existing treatments 
improved dramatically over the past decades and we are now moving toward HAE 
personalized therapy. 
Human C1 inhibitor (hC1-INH) is a pluripotent plasma glycoprotein with a vast 
number of biologic effects and a possibly growing number of therapeutic applications 
[36]. Considering the large spectrum of physiologic functions, it seems reductive to 
consider genetic C1-INH deficiency just as a condition exposing to angioedema 
recurrences and limit therapeutic intervention to avoid this symptom. Accordingly, 
reversal of the genetic deficiency appears as the approach closest to restore 
physiologic homeostasis. Recombinant approaches for production of C1-INH started 
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in late 1980s aimed at understanding structure-function correlates of disease 
causing mutations [37,38]. Recombinant human C1-INH (rhC1-INH) has been 
produced from mammalian cell culture, bacterial and yeast-based expression 
systems to be used for research, but these systems were never applied to products 
for use in humans [39]. This may be explained by rhC1-INH poor expression levels in 
the culture, its inactivation throughout the production process, and/or the non-
mammalian glycosylation profiles of these methods. The expression of rhC1-INH in 
the milk of lactating transgenic animals provides an alternative to the initially 
investigated culture-based expression systems. It provides high rhC1-INH 
expression levels (up to 12 g/l) and mammalian glycosylation profiles as reported for 
different human proteins [40,41]. The rabbit as a transgenic platform gives some 
specific advantages as relatively short gestation period and safe environment to 
minimize adventitious agents in the production process. Translated into therapeutic 
product, these characteristics predict infectious safety and production easily sized to 
demand. In terms of biologic characteristics, conestat alfa has protease inhibitory 
properties identical to those of the human plasma protein and significant 
pharmacokinetic differences likely depending on species specific peculiarities in 
glycosylation [42]. We aim at discussing further in detail these aspects. (Table 1)  
2.2. Introduction to the drug  
Conestat alpha is a rhC1-INH (Ruconest®, Pharming Technologies B.V., Leiden, 
The Netherlands) obtained through a purification process of transgenic New Zealand 
white rabbits’ milk (Oryctolagus cuniculus). The promoter used to drive expression of 
the hC1-INH transgene is the bovine alpha-S1-casein promoter, which is specific for 
the secretion of caseins in the milk. The protein content of rabbit milk is 
approximately 14% of which about 65% consists of various caseins aggregated in 
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micelles. The remaining proteins in rabbit milk are whey proteins including 
transferrin, whey acidic protein, immunoglobulins, albumin and lactalbumin. After 
collection, rabbit milk undergoes series of standard centrifugation, filtration, and 
chromatography steps that give rhC1-INH, 99% purity as assessed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis [43]. The 1% impurities are 
multimers and N-terminal cleaved C1-INH species. Host-related impurities were 
analysed (ELISA) and measured to be approximately 10 ppm in the commercial 
batches and defined to consist of minimal traces of rabbit protein. [43]. The activity of 
purified rhC1-INH is 6.1 U per mg of protein, the same as pdC1-INH [43]. Protein 
sequencing analysis of recombinant and plasma proteins reveals identical 
polypeptide N- and C-terminals for the two molecules. Nevertheless, the two proteins 
differ in molecular mass and this is explained by differences in glycosylation (21% 
and 26-28% carbohydrate content resp ctively) [43,44].  
Conestat alfa and pdC1-INH showed kinetics for inhibition of C1s, kallikrein, FXIIa, 
and FXIa comparable in terms of protein potency and specificity. Observed 
differences in the various studies can be explained by the different methods used for 
the experiments, and the differences of the protocol followed for sample collection by 
the investigators. [25,42,43]. (Table 1)  
2.3. Chemistry and biology: SERPIN vs. Non-SERPIN part of C1-INH 
Sequence analysis demonstrates that the C1 inhibitor is a member of serin protease 
inhibitors (serpin) superfamily. The molecule consists of two distinct domains that 
may be observed by electron microscopy [45]. The serpin domain extends from the 
carboxy-terminal, contains the reactive site and is responsible for protease inhibitory 
function. A rod-like amino-terminal of about 100 aa represents the non-serpin 
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domain. It shows no significant homology with any known protein and its amino 
acids’ most striking characteristic is the presence of 10 glycosylation sites [46].  
As for other serpins, C1-INH consists of alpha-helices and beta-sheets, as well as an 
exposed mobile reactive center loop that is cleaved upon contact with a target 
protease [47]. This reaction results in the formation of a stable, covalent bond. 
Protease binding causes dramatic conformational changes in C1-INH, which crushes 
the protease against its lower pole resulting in irreversible inactivation of the enzyme. 
This defines serpins to be “suicidal” protease inhibitors. (Figure 2) 
C1-INH inactivates a variety of proteases including complement system proteases 
(C1r, C1s, MASP2), contact system proteases (factor XII, plasma kallikrein), an 
intrinsic coagulation protease (factor XI) and the fibrinolytic proteases (plasmin). 
(Figure 1) (For detailed review see Davis) [48]. 
The highly mobile N-terminal of the protein is comprised of 97 amino-acids, and the 
attached sugars probably being of greater biologic importance than its non-compact 
polypeptide chain. This N-terminal, elongated domain, probably plays the role of an 
“anchor”, helping the C1-INH molecule to “attach” to different surfaces. It does not 
directly contribute to protease inhibition and establishes non-covalent interactions 
with other proteins, and cell surfaces or lipids [36,49,50].  
Differences in the N-terminal glycosylation (see Table 1) modify the 
pharmacokinetics of the molecule. The removal of sialic acids from C1-INH (asialo-
C1-INH) is found to significantly enhance its clearance from the circulation showing a 
half-life of 3 to 5 min in an investigational rabbit model [51]. This effect is presumably 
conducted via its binding to asialo-glycoprotein receptors in the liver with enhanced 
clearance due to exposure of the penultimate galactosyl residue. Subsequent 
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removal of the latter reverts the clearance rate up to values similar to that of normal 
C1-INH [51]. Though, the removal of sialic acid or galactose groups does not impair 
the protease inhibitory function of C1-INH in vitro [51]. 
As expected, rhC1-INH produced in transgenic rabbits differs from C1-INH produced 
in humans in the glycosylation profile. In fact, each animal adds sugar-to-protein with 
a pattern specific of the species, and furthermore, differences might occur between 
different tissues within the same species. 
a. Pharmacodynamics  
Genetically low C1-INH function, lessens the control of the esterase activity that 
generates upon spontaneous formation of the C1 complex. Such an inefficient 
control allows cleavage of the natural substrates of C1, C4. In HAE patients, neo-
synthesis of C4 cannot compensate consumption resulting in characteristically low 
plasma levels. Reversal of C4 consumption with normalization of plasma levels has 
been used as biomarker for therapies target to C1-INH replacement. Accordingly, 
pharmacokinetic curve of conestat alfa at doses of 100 and 50 U/Kg, shows a dose-
dependent restoration of C4 consumption measured by decrease of C4 break-down 
products (C4b/c) and parallel increase of C4 plasma levels [42]. C4 peaks 
approximately 12 hours post-infusion and then gradually reverts to baseline levels. 
When post-infusion C1-INH functional plasma fall below 0.7 U/ml, C4 consumption 
resumes. Doses below 25 U/kg have minimal effect on C4 plasma levels. 
Pharmacodynamics effect of rhC1-INH is measured as reduction in the amount of 
cleaved high-molecular-weight kininogen (cHK), indirect marker of bradykinin 
formation. Cleaved HK increases during attacks in HAE and in inter-critical periods 
discriminates frequently symptomatic patients from those suffering rare angioedema 
Page 10 of 36
URL: https://mc.manuscriptcentral.com/erm   Email: jonathan.patience@informa.com
Expert Review of Clinical Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 11
symptoms [52]. Conestat alfa in doses of 50 U/Kg significantly reduces cHK [53]. 
b. Pharmacokinetics and metabolism of rhC1-INH 
Plasma levels of C1-INH in the normal population range from 70 to 130% (0.7–1.3 
U/ml). In a large HAE population, functional levels of C1-INH ranged between 10% 
and 30% [54]. In the open-label escalation study with conestat alfa in asymptomatic 
HAE patients (doses from 6.25–100 U/ kg) there is a dose-dependent increase in 
functional C1-INH activity up to normal for doses of 50 and 100 U/kg [42]. Elimination 
half-life derived from this study is 1.6 and 2 hrs, which is clearly shorter compared to 
plasma C1-INH. The fractional catabolic rate of radiolabelled C1-INH purified from 
normal plasma, is 0.025 of th  plasma pool/hour in normal subjects and 0.035 in 
HAE patients [55]. These catabolic rates correspond to a half-life 20 and 14 hours 
respectively. When pdC1-INH for therapeutic use substitutes the radiolabelled 
protein, the estimated post-infusion half-life shows great variability among studies. 
Using Berinert, it is 39.1 hrs, with Cinryze 56 hrs [12,56].  The conditions of these 
studies are extremely different and head to head comparison among preparations is 
not appropriate. Nevertheless, the strikingly shorter half-life of the recombinant 
protein is evident. It is explained by the glycosylation profile of the recombinant 
product that enhances binding to asyaloglycoprotein and mannose receptors that are 
abundant in the liver and rapidly clear the protein from the circulation. The dose-
dependent increase of the half-life of rhC1-INH is ascribed to saturation of these 
receptors [42]. However, the clinical efficacy of conestat alfa does not appear to be 
affected by the shorter plasma life. A meta-analysis of controlled studies of efficacy 
of on demand pdC1-INH and rhC1-INH, shows a dose dependent increase, which is 
independent from the pharmacokinetic characteristics of the different products [57]. 
A model of population pharmacokinetic (PPK) analysis used data from 120 subjects 
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who received 214 administrations of rhC1-INH during 6 clinical studies [58]. Using 
the Michaelis-Menten elimination kinetics model, a single dose of rhC1-INH of 50 
U/kg would restore normal functional C1-INH levels in more than 94% of C1-INH-
HAE patients. This suggests that doses below 50U/Kg prevent a vast number of the 
patients from achieving C1-INH levels within the normal range [57]. The PPK model 
confirms the importance of a weight-based dosing of rhC1-INH up to a dose of 4200 
U (two commercial vials). The PPK model was also used to investigate differences in 
peak C1-INH activity levels after initial administration compared to repeated 
administrations for subsequent HAE attacks, and indicated no such differences [58].  
d) Clinical development of conestat alfa 
Phase I studies – an open-label dose-escalation study 
The study protocol for this open-label dose-escalation study was conducted in 12 
asymptomatic subjects with a typical medical history of HAE with functional C1-INH 
and C4 levels of less than 40% of normal. All subjects were symptom free for a 
period of at least 2 weeks before rhC1-INH was administered for the purpose of the 
study. The patients were divided into 4 groups of 3 patients (starting from 6.25, 12.5, 
25, and 50 U/kg, respectively) and each patient was given 2 doses of rhC1-INH with 
a washout period of at least 5 weeks before the dose was escalated up to 100 U/kg. 
The course of functional C1-INH in plasma showed a full initial recovery and a dose-
dependent clearance of rhC1-INH. The observed safety profile and biologic activity 
of rhC1-INH suggested further clinical studies to assess its efficacy in treating acute 
HAE attacks [42].  
On demand treatment of acute attacks 
The efficacy of rhC1-INH for the treatment of HAE patients during acute angioedema 
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attacks has been demonstrated in several studies, including three double-blind, 
placebo-controlled efficacy studies [15,29] and five open-label studies where patients 
maintained treatment of subsequent attacks [29,30,32,34,59]. No relapse or rebound 
episodes were reported, suggesting that conestat alfa mechanism of action and 
specific pharmacodynamics, lead to sustained protein activity, rather than its 
relatively short elimination plasma half-life. In the largest of these studies (n = 224 
attacks treated), 96% of attacks were treated with a single dose of rhC1-INH of 50 
U/kg (max 4200 U) [30]. Moreover, administration of an additional treatment dose 
was not reported for subsequent attacks.  
Prophylaxis 
The efficacy of rhC1-INH for prophylactic treatment of patients with HAE to prevent 
onset of angioedema attacks has been investigated in two studies, one open label 
pilot study and one double-blind, randomized, placebo-controlled study [33,34]. 
Extension for the indication has been submitted and waiting for approval, expected in 
the third quarter of 2018 [60].  
Open-label pilot prophylaxis study in HAE  
An open-label, uncontrolled, pilot study to test efficacy and safety of prophylactic 
once-weekly administration of conestat alfa at 50 U/kg was conducted over an 8-
weeks period in patients with high frequency of monthly attacks [34]. The study 
enrolled 25 patients with a mean attack-rate of 0.9 attacks per week (median of 0.6 
attacks, range 0.4 to 4.5 attacks per week). The mean breakthrough attack rate 
during the treatment period was 0.4 attacks per week (median of 0.3, range from 0.0 
to 1.5 attacks per week), which showed to be significantly lower than the reported 
historical average attack rate.  
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Randomized placebo-controlled trial for prophylaxis of HAE  
Recently, the results from a phase II multi-centre, randomized, double-blind, 
placebo-controlled, 3-period cross-over study were published [33]. The study aimed 
at evaluating the efficacy and safety of conestat alfa in prophylaxis of angioedema 
attacks within adult and adolescent patients with severe course of C1-INH-HAE. 
Eligible patients were those above the age of 13 years with a clinical history of 
frequent HAE attacks (>4 attacks per month). Each patient received three 4-week 
periods of treatment, twice weekly, with a 1-week washout between different 
treatment periods. The study was conducted in 32 (ITT) patients (26 completed the 
study) who received intravenously in a double-blind fashion injection of conestat alfa 
50 U/kg (to a maximum of 4200 U for patients ≥84 kg), either once weekly or twice 
weekly. The outcomes reported by the authors were that the mean number of 
attacks of hereditary angioedema over 4 weeks was significantly reduced with 
conestat alfa twice weekly, and once weekly, versus placebo, with mean differences 
of –44 attacks (p<00001) and –28 attacks (p=00004), respectively [33].  
In addition, prophylaxis with conestat alfa for HAE has been reported in sporadic 
case report series, both used in long-term prophylaxis, and as a successful choice in 
short-term prophylaxis before deemed invasive procedures [35]. (Table 2) 
e) Post marketing surveillance  
The database following safety and tolerability of conestat alfa includes clinical and 
laboratory data arising from almost 1600 administrations of rhC1-INH in twelve 
completed clinical development program studies. [53]  
Adverse events: 
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The safety data analyses demonstrate that rhC1-INH at doses of 50 IU/kg and 100 
IU/kg is generally safe and well tolerated when administered for treatment and 
prevention of HAE attacks. The adverse event profile found in the randomized, 
placebo-controlled studies was similar for patients treated in the rhC1-INH and saline 
treatment groups. There was no increase in the incidence of treatment-emergent 
adverse events with higher rhC1-INH dose, administration of additional rhC1-INH 
doses for an attack, or with repeated treatment of subsequent attacks [30]. The most 
common adverse reactions (≥ 2%) reported in all clinical trials were headache, 
nausea and diarrhea.  
Important for clinical practice is to avoid using the product in patients who are rabbit 
allergic due to potentially serious allergic reactions, which has happened within three 
minutes after administration of conestat alfa in only a single healthy volunteer with a 
pre-existent (retrospectively known), non-disclosed rabbit dander allergy [42]. 
Throughout the clinical development of the drug, no safety issue related to 
hematology, biochemistry, coagulation, urinalysis, vital signs, or ECG parameters 
was noted. 
Thrombogenicity: 
Concerns regarding a thrombogenic risk of conestat alfa, or regarding a clinically 
meaningful effect on activation of coagulation or fibrinolysis (due to its effect on 
proteases of the contact/coagulation system and previous reports in high-dose 
treatment with plasma-derived C1-INH) have not been recorded during clinical 
development and clinical studies. Conestat alfa did not show effect on activation of 
coagulation and fibrinolysis [61]. In fact, D-dimer levels, which are considered 
biomarkers of thrombosis were followed during acute treatment with conestat alfa 
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and treatment was not associated with thrombotic events [62]. 
Immunogenicity: 
Immunogenicity of rhC1-INH was extensively tested throughout the clinical 
development programs, supporting that conestat alfa has low potential to induce 
anti-C1-INH antibodies or anti-host-related impurities (HRI) response. 
Confirmed antibodies against C1-INH or HRI were observed infrequently and were 
not associated with clinical symptoms indicating hypersensitivity or changes in rhC1-
INH efficacy [63]. 
There was no association between treatment-emergent adverse events or new acute 
HAE attacks and the presence of any confirmed anti-C1-INH or anti-HRI antibodies.  
No patients were tested positive for neutralizing antibodies to endogenous C1-INH or 
rhC1-INH. No anti-rabbit IgE antibodies were reported elevated with treatment with 
conestat alfa and moreover, no severe hypersensitivity reactions were reported 
beyond the single case in a Phase 1 study and in the post-approval phase as of the 
date of the manuscript preparation. (Table 3) 
f) Regulatory affairs 
RhC1-INH started to be investigated as a potential pharmacological agent in the 
treatment in HAE with various clinical studies conducted since the late 1980s 
[43,64,65]. Subsequently, the registration of the drug conestat alfa (Ruconest®) was 
secured in 2010 in Europe, and following in 2014 in the USA and Israel.  
The European Commission has granted rhC1-INH (Ruconest®) a marketing 
authorization for the treatment of acute angioedema attacks in adults and 
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adolescents with HAE due to C1-INH deficiency. Currently, it is now approved for 
use in all the 28 EU member countries plus Norway, Iceland and Liechtenstein. 
The United States’ Food and Drug Administration (FDA) approved rhC1-INH 
(Ruconest®) for the treatment of acute angioedema attacks in adult and adolescent 
patients with C1-INH-HAE. Because of the limited number of patients with laryngeal 
attacks, effectiveness was not established in HAE patients with laryngeal attacks by 
the FDA. 
Conestat alfa is approved in Israel for the treatment of acute angioedema attacks in 
adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. 
Conestat alfa is approved in South Korea for the treatment of acute angioedema 
attacks, except oro-pharyngeal & laryngeal locations in adult patients with hereditary 
angioedema. 
In the pediatric population (2-13 years old), the study has been completed and 
submitted for approval, awaiting to expand the indication in this subpopulation 
(https://www.pharming.com/pharming-announces-positive-data-from-paediatric-
clinical-trial-with-ruconest/).  
3. Conclusion 
Hereditary angioedema (HAE) is a rare autosomal dominant disease characterized 
by recurrent swellings of the extremities, oro-facial-pharyngeal zones, upper airways, 
genitalia, often severely disrupting patients’ lives. HAE is a potentially life threatening 
disease, with 1-5% of all angioedema episodes locate to the larynx. In absence of 
appropriate diagnosis and treatment 25% of patients die for laryngeal edema [10]. 
The burden of HAE has huge geographical discrepancy due to differences in 
treatment availability. In the recent years, new drugs for C1-INH-HAE were approved 
in Europe and North America. Available treatments can be seen as optimal to avoid 
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mortality granted unrestricted availability and education for appropriate use. In terms 
of minimizing morbidity, on demand approach is insufficient for frequently 
symptomatic patients; attenuated androgens are limited by side effects and 
intravenous pdC1-INH by administration route and empiric optimal dosing. Raising 
demand for optimal prophylaxis, pushed towards development of novel hi-technology 
approaches based on different platforms. Subcutaneous pdC1-INH, already 
available in U.S., and upcoming prophylactic approaches tackling plasma kallikrein, 
should further improve treatment efficacy and customization. Using transgenic 
animal technology, rhC1-INH aims at providing replacement therapy with a human 
protein produced by recombinant technology that is free from blood borne human 
infectious agents and in transgenic animal that allows to scale production based 
upon request. The recently published phase II study demonstrates that the short 
half-life of the rhC1-INH does not lessen efficacy as prophylactic therapy. Safety, 
tolerability and efficacy on repeated infusions, relay on the long development 
program that brought rhC1-INH registration in Europe, USA, Israel, and other 
countries for treatment of acute HAE attacks in adult and adolescent patients. The 
same intravenous formulation was used to obtain evidence for effective in 
prophylaxis. In the presence of subcutaneous and oral competitors prophylactic 
therapy administered intravenously, cannot be successful. A concentrated 
formulation of conestat alfa for subcutaneous or intramuscular administration is 
expected to bring this product into the market for HAE prophyalxis. When such a 
low-volume formulation will prove as effective as competitors in large number of 
patients followed for several months, the compound will become an interesting 
additional alternative for patients with HAE. 
4. Expert commentary  
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C1-INH is an acute-phase protein that for structure and inhibitory mechanism 
belongs to the superfamily of serine-protease inhibitors. Soon after discovery that 
genetic C1-INH deficiency was the cause of HAE, C1-INH derived from human 
plasma became the life-saving drug for these patients. Technological evolution and 
improved safety expanded the indication of plasma derived products are now used 
as replacement therapy in genetic defects. This is true also for C1-INH, established 
treatment for long-term prophylaxis of HAE. Need for large supply of safe proteins, 
prompted to develop the recombinant technology in transgenic animals. Conestat 
alfa, the recombinant human C1-INH purified from milk of transgenic rabbits, was 
initially approved as on demand intravenous therapy. When long-term replacement 
of C1-INH deficiency by the plasma derived protein became a standard approach to 
the disease, conestat alfa was considered for analogous use. Main drawback to 
foresee this product as successful for prophylaxis was its short half-life. Six hours 
after infusion conestat alfa is not detectable in patients’ plasma. Nevertheless, 
analysis of data from on demand trials showed that clinical efficacy of plasma and 
recombinant C1-INH was dependent on the initial dose and not influenced by the 
pharmacokinetic profile. Moreover, an animal model of stroke, showed rhC1-INH to 
be superior to the pdC1-INH in protecting from extension of the ischemic brain injury 
[66]. Such a difference appeared to be explained by the stronger affinity of rhC1-INH 
for mannan binding lectin (MBL) and thus better inhibit the lectin pathway of 
complement: rhC1-INH binds MBL with a relatively high affinity 
(230nM), whereas pdC1-INH does not show any binding up to 40um [67]. Thus, the 
possibility that clearance from the circulation did not necessarily mean protein 
catabolism was considered. Normal C1-INH binds to endothelial cells maintaining 
intact protease inhibitory activity [68]. C1-INH binding characteristics have been 
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investigated to explain other potential anti-inflammatory effects of human C1-INH 
[49]. These effects do not appear to require protease inhibition and depend on non-
covalent interactions with other proteins, cell surfaces or lipids. C1-INH is a multi-
faceted anti-inflammatory protein that acts through a variety of mechanisms including 
protease inhibition in addition to several different non-covalent interactions, not 
related to its anti-protease activity.  
Thus, efficacy of conestat alfa, administered once or twice per week, in HAE 
prophylaxis was tested on the hypothesis that rhC1-INH is still biologically active 
after disappearance from the circulation. The promising results of the two studies 
where conestat alfa was tested as prophylactic agent suggest that the hypothesis is 
valid. In order to become an alternative for replacement therapy in HAE patients, a 
low-volume subcutaneous or intramuscular formulation of conestat alfa needs to 
demonstrate to be as effective as the plasma-derived protein.  
The possibility that rhC1-INH has biologic activity independent from plasma levels 
opens to the possibility of indications outside from HAE. Plasma derived C1-INH and 
rhC1-INH have been studied in a variety of animal models of diseases involving 
contact and complement system. Among others, pancreatitis, sepsis, thermal injury, 
xenotransplantation, and various models of ischemia-reperfusion injury (e.g., 
myocardial infarction, stroke, delayed graft function in transplantation) 
[69,70][71,72][73][74][75,76][77]. The efficacy of C1-INH in humans with these 
disease states needs to be assessed by appropriate studies. When such studies will 
be designed the different efficacy of plasma and recombinant products will have to 
be considered taking into account the findings in the animal model of stroke.   
5. Five-year view 
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In a five-year period, we can easily envisage that HAE prophylaxis with androgens 
will be marginal in countries where new treatments are available. On demand 
treatment and prophylaxis will still co-exist due to the high variability in symptom 
frequency. In the field of prophylaxis two approaches will compete: replacing the 
genetic defect versus silencing the generation of the angioedema mediator. Both 
appear to provide nearly complete prevention of symptoms and decision will rely on 
expected long term benefit and patient preference. C1-INH replacement appears 
more physiologic and some long-term experience is already available to confirm 
absence of side effects. Theoretical positive aspect for C1-INH is the possibility to 
prevent, along with angioedema, the consumption of classical pathway complement 
components. Genetic defects of the components of this pathway are associated with 
reduced apoptosis and autoimmunity [78]. We still lack data showing whether C1-
INH deficiency exposes to diseases other than angioedema. In a short, while HAE 
registries will make this information available facilitating therapies tailored on 
patients’ needs. This is part of a general trend towards personalized/precision 
medicine aimed at restoring the physiologic state in respect of personal needs. Non-
trivial to this is treatment administration modality. In 5 years, we will still have HAE 
patients controlling the disease with an on demand approach or others with 
prophylaxis. For the last approach there will be subcutaneously injectable treatments 
delivered every few days or every month, as well as daily tablets. Choosing between 
the different options depends mainly on patients’ attitude. There are patients who 
just want to forget the disease and others, who prefer to maintain an active control. 
The different options will likely satisfy most of these needs.  
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To close, we can predict that in 5 years extended information on disease variability 
and a large array of treatment options will render HAE the prototype of successful 
precision medicine. 
6. Key issues 
• Hereditary angioedema (HAE) results from an autosomal dominant hereditary 
deficiency of the plasma protein C1 inhibitor (C1-INH-HAE) and is 
characterized by the occurrence of acute attacks of angioedema that can be 
life-threatening, disfiguring and/or disabling.   
• Recombinant human C1-INH (rhC1-INH) is approved for the treatment of 
acute angioedema in adult and adolescent patients with HAE.   
• A recent publication from a phase 2 randomized double-blind, placebo 
controlled, cross-over trial has presented data about rhC1-INH as an 
efficacious agent for prophylactic treatment of HAE in adult and adolescent 
patients, which confirms the previously reported data from an open label pilot 
study and sporadic case reports.   
• C1-INH is a human plasma protein involved in the regulation of the 
complement, coagulation, fibrinolysis, and contact systems. It is a powerful 
controlling protein in early stages of these bio-amplification cascades, and in 
that way, a crucial regulating factor of the innate immune response. 
Therefore, its role could be further investigated as a potential controller agent 
in various cases of abnormal inflammation.  
• Recombinant human C1 inhibitor (rhC1-INH) has some distinguishing 
features, when compared to plasma-derived C1-INH, probably related to the 
difference in the glycosylation of the non-serpin N-terminal of the molecule. 
These specificities account for the differences in its pharmacokinetic 
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behaviour (e.g. shorter plasma half-life), as well as its stronger affinity to 
suppress the lectin complement pathway.  
• Further studies are needed to explain rhC1-INH behaviour in the human body, 
as the drug’s plasma half-life of clearance is not a sufficient predictor of its 
efficacy.  
7. Information resources 
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/   
Clinical trials.gov registry and database of clinical studies of human participants: 
https://clinicaltrials.gov   
Pharma companies’ websites: www.ruconest.com, www.cinryze.com, 
www.berinert.com, www.haegarda.com 
 
Regulatory affairs: www.ema.europa.eu, www.fda.gov   
 
  
Page 23 of 36
URL: https://mc.manuscriptcentral.com/erm   Email: jonathan.patience@informa.com
Expert Review of Clinical Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 24
Legends: Figures and Tables 
 
Figures: 
 
1. Figure 1: Bio-amplification plasma cascades and C1-INH. 
2. Figure 2: C1-INH: mechanism of action with proteases 
 
Tables 
3. Table 1: Characteristics of recombinant human and plasma-derived C1-INHs 
4. Table 2: Clinical efficacy: studies with rhC1-INH for prophylaxis 
 
5. Table 3. Safety and tol rability of rhC1-INH and competitors for prophylaxis of 
HAE 
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1. Table 1: Characteristics of recombinant human and plasma-derived C1-INH 
Characteristics of C1-INH  
Classification Serine protease inhibitor, serpin 
Synonyms C1-esterase inhibitor, C1s-inhibitor, C1-inactivator,  alpha2-neuramino-glycoprotein, Serpin Family G member 1 
Activity/Function 
C1-inhibitor controls activation of the C1 complex and the generation of kinins. It inhibits the target proteases by 
the formation of a proteolytically inactive stoichiometric complex. It regulates proteases in complement, contact, 
coagulation and fibrinolytic systems. 
Cofactors Glycosaminoglycans 
 
Characteristics of commercially available C1-INH for the treatment of HAE 
Properties Recombinant human C1 inhibitor (conestat alfa) Plasma derived C1 inhibitors 
Target proteases C1s, C1r, aFXIIa, bFXIIa, kallikrein, FXIa, plasmin, MASP-1, MASP-2 
Mature polypeptide sequence Identical, 478 amino acids 
Apparent Molecular Weight* kDa  
(SDS-PAGE) 
98 [25]  105 [25] 
Molecular Weight** kDa  
(mass spectrometric analysis) 
67 [43] 74-71[44] [43]  
Carbohydrate contents (w/w) 21% [43]  28-26% [43,44] 
Glycosylated amino-acids 
(mature protein) 
Not reported 
Multiple O-linked and 6 N-linked glycans:  
Six N-glycosylation sites at Asn-3, -47, -59, -216, 
-231, and -330. Seven O-glycosylation sites at 
Ser-42 and Thr-26, -49, -61, -66, -70, and -
74[44]. Another study reported 24 O-glycosilation 
sites [46]  
Type of sugar residues 
N-glycans  of oligomannose-, hybrid-, and complex-type 
structures. 25% are neutral and the remaining are 
sialylated (N-acetylneuraminic acid only). Of these. 67% 
are monocharged of the hybrid-, mono- or diantennary 
complex type. Part are (a1-6)-core-fucosylated or (a1-3)-
fucosylated in the lower or upper antenna (Lewis x 
epitope). Small core 1-type O-glycans with the usual (a2-
3)- and (a2-6)-sialylation pattern of O-glycoproteins of 
nonmucinous origin [28] 
 (α2-3)-disialylated and (α2-6)-disialylated 
complex-type diantennary N-glycans (molar ratio, 
2:1). (α2-3)- monosialylated core 1-type O-
glycan. The N-glycans are (α1-6)-core-
fucosylated for 30%, and the only sialic acid 
found is N-acetylneuraminic acid. Lower amounts 
of sialylated tri- and tetraantennary structures are 
also reported [44] 
Plasma half-life of clearance (hours) 
1.6 (50 U/kg) [42] 
2.9 (100 U/kg) [42] 
10 – 96 [79-81] 
Activity (concentration) U/mL 150 [25] 50-100 [25] 
Genetics 
Human C1-INH gene sequence through a bovine alpha-
S1-casein promoter, specific for the secretion of caseins in 
the milk, introduced via micro-injection transgenic 
technique in New Zealand white rabbits (Oryctolagus 
cuniculus) 
17-kilobase single-copy gene on human 
chromosome 11, which consists of eight exons  
Synthesis 
New Zealand white rabbits mammary gland epithelial cells 
and secreted in the milk 
Human hepatocytes, fibroblasts, monocytes, 
macrophages, endothelial cells, amnionic 
epithelial cells, and perhaps cells in the microglia 
Final purity of the commercial drug 
Purity 99% [25] 89 – 97 % [25] 
Impurities 
1% rhC1-INH multimers and N-terminal cleaved C1-INH 
species [25,43] 
3 – 11 % low and high-molecular weight proteins 
[25] 
Host related impurities 
10 ppm, traces of rabbit protein; 
No endogenous rabbit C1-INH [25] 
Human α1-antichymotrypsin and ceruloplasmin, 
C3, immunoglobulin heavy constant mu [25] 
Kinetics, second-order rate constant Kon (M
-1s-1)  
(higher values correspond to higher inhibitory capacity) 
C1s 6.1 x 10x4 [43] 
5.1 x 10x4 [43] 
4.8 x 10x4 [64] 
6.2 x 10x4 [39] 
Factor XIa 9.8  x 10x2 [43] 
9.0 x 10x2 [43] 
1.8 x 10x3 [82]  
3.9 x 10x2 [39]  
Factor XIIa 6.9 x 10x3 [43] 
5.7 x 10x3 [43] 
9 x 10x3 [82]  
4.5 x 10x3 [39]  
Kallikrein 9.1 x 10x3 [43] 
7.6 x 10x3 [43] 
2.6 x 10x4 [82]  
7.8 x 10x3 [39]  
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Legend: C1-INH, C1 esterase inhibitor; rhC1-INH, recombinant human C1 inhibitor; pdC1-
INH, plasma-derived C1 inhibitor; GAGs, glycosaminoglycans, HAE, hereditary angioedema; 
C1s, complement C1s; C1r, complement C1r; FXII, factor XII; FXI, factor XI; MASP1/2, 
mannan-binding lectin serine protease 1/2; C-terminal, protein carboxyl-terminus; N-
terminal, protein amino-terminus; C3, complement C3.  
* Measured by Sodium Dodecyl-Sulfate polyacrylamide gel electrophoresis 
** Measured by fine neutron scattering 
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Table 2: Clinical efficacy: studies with rhC1-INH for prophylaxis 
 
 
Study 
Number 
Phase of study Subjects Therapeutic regimen Results Reference 
NCT00851409 
 
Pilot phase II open-
label prophylaxis 
study  
Adult C1-INH-HAE 
patients with 
history of at least 2 
attacks/month  
 
N=25 (ITT) 
Weekly administration 
of 50 U/kg conestat 
alfa 
Mean weekly attack rate 
decreased during the 
study to 0.4 
attacks/week, as 
compared with the pre-
study attack-per-week 
rate of 0.9  
[34] 
      
NCT02247739  
Phase II multicenter, 
randomized, double-
blind, placebo-
controlled, 3-period 
cross-over study  
≥13 years older 
C1-INH-HAE 
patients with 
history of at least 4 
attacks/monthly in 
the last 3 months 
prior to study 
enrollment 
 
N=32 (ITT) 
Three 4-week-periods 
of intravenous 
injection of conestat 
alfa 50 U/kg (to a 
maximum of 4200 U 
for patients ≥84 kg), 
either once or twice 
weekly with a 1-week 
washout between 
treatment periods 
The number of attacks 
of hereditary 
angioedema over 4 
weeks was significantly 
reduced with conestat 
alfa twice weekly, and 
once weekly, versus 
placebo, мean 
differences of –44 
attacks (p<00001) and 
–28 attacks (p=00004), 
respectively 
[33] 
      
 
C1-INH-HAE, hereditary angioedema due to C1 inhibitor deficiency; 
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Table 3. Safety and tolerability of rhC1-INH and competitors for prophylaxis of HAE 
 
Drug (molecule) 
 
Commercial 
name, Company 
 
Subjects and therapeutic 
regimen 
Adverse events 
Warnings and 
precautions 
References 
rhC1-INH 
Ruconest, 
Pharming B.V. 
Adults and adolescents; 
50 IU/kg, twice weekly, I.V. 
(up to 4200 IU for ≥84kg) 
Headache, nausea 
and diarrhea  
Potentially serious allergic 
reactions in rabbit allergic 
patients. 
Potential immunogenicity. 
[15,29-
31,34,42,55,63,83,84] 
 
SPC of the product  
pdC1-INH 
Cinryze,  
Shire 
Adults and adolescents; 
1000 IU, twice weekly, I.V. 
(up to 2500 IU, but no more 
than 100 IU/kg) 
Headache, nausea, 
rash, vomiting and 
fever 
Potential infectious agents’ 
transmission. 
Thrombotic and 
thromboembolic events. 
Allergic reactions. 
Potential immunogenicity. 
[13,22,85,86] 
 
SPC of the product  
Low-volume  
pdC1-INH 
HAEGARDA,  
CSL Behring 
Adults and adolescents; 
60 IU/kg, twice weekly, 
S.C. 
Injection site 
reactions, 
hypersensitivity, 
nasopharyngitis, and 
dizziness 
Potential infectious agents’ 
transmission. 
Potential thrombotic 
events. 
Potential tachyphylaxis. 
[18,87] 
 
SPC of the product  
 
NCT01576523 
NCT01912456 
NCT02316353 
Rh mAb 
targeting plasma 
kallikrein 
Lanadelumab,  
Shire 
Adults and adolescents; 
150 mg, once monthly, 
S.C. 
or 
300 mg, once or twice 
monthly, S.C. 
Injection site 
reactions, headache, 
nasopharyngitis, rash, 
and dizziness 
Potential immunogenicity. 
Theoretical precaution for 
cardiovascular accidents, 
bleeding and autoimmune 
disorders 
[19,33,88] 
 
NCT02586805 
 
Ongoing Phase III 
      
 
rhC1-INH, recombinant human C1 inhibitor; pdC1-INH, plasma-derived C1 inhibitor; HAE, 
hereditary angioedema; I.V., intravenously; S.C., subcutaneously; SPC, summary of product 
characteristics; rh, recombinant human; mAb, monoclonal antibody. 
 
*Other prophylaxis options as androgens and tranexamic acid were not included as the data has 
been previously summarized in other review articles [89] 
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